New Health Campaign Urges People With Diabetes To 'TALK Hypos'

New Health Campaign Urges People With Diabetes To 'TALK Hypos'

GATWICK, England, Sep 25, 2014 (PR Newswire Europe via COMTEX) -- GATWICK, England, September 25, 2014 /PRNewswire/ --

Potentially dangerous diabetes symptom currently goes unreported to healthcare professionals

Today marks the launch of the TALK Hypos awareness campaign, supported by Novo Nordisk and Diabetes UK, which aims to encourage people with diabetes to report hypoglycaemia (hypos) to their doctor or nurse. The TALK Hypos campaign launches to coincide with Hypo Awareness Week (29 September-5 October 2014).

There are about 3.2 million people diagnosed with diabetes in the UK[1] and hypos are one of the most common diabetes complications.[2] Hypos are when glucose in the blood falls to a low level, and symptoms can include a pounding heart, trembling, hunger, difficulty concentrating and blurred vision.[3] Left untreated, hypos can become serious and cause unconsciousness.[4] Despite this, hypos remain under-recognised[5] and under-reported[6] by patients.

Simon O'Neill, Director of Health Intelligence for Diabetes UK, said, "People with diabetes can fail to report hypos to clinicians for a range of reasons, including lack of awareness, a fear of losing their driving licence and a belief that their healthcare professional is unable to make a difference. To make matters worse, we know that people with diabetes and their families are often fearful of hypos and feel powerless to do anything.

"The first step is to help people with diabetes recognise the symptoms of hypos and better manage their condition by encouraging a regular discussion about them during consultations. We are pleased to be involved in a campaign which aims to do just that."

TALK Hypos provides an acronym to encourage people with diabetes to discuss hypoglycaemia with their doctor or nurse:

- THINK: Do you know what a hypo is? Do you suffer from hypos? - ASK: your doctor or nurse about hypos and discuss them as part of your consultation - LEARN: what can be done to better manage your hypos, including lifestyle and treatment options - KEEP: track of your hypos for discussion with your healthcare professional
As well as the more immediate symptoms, a few people may experience severe hypos, which can require emergency assistance. Regularly occurring severe hypos have been linked to longer-term health complications including, in some instances, heart disease.[6] Having repeated hypos can, over time, lead to 'hypo unawareness', where the warning symptoms of a hypo are no longer felt, making hypos harder to identify and more difficult to manage.[6]

Simon O'Neill added, "We would encourage all people with diabetes to remember the simple TALK Hypos message and to remember that steps can be taken to better manage hypos, including simple changes to lifestyle, diet and treatment. It is very important to discuss hypos as part of the regular consultation with your doctor or nurse."

Klaus Henning Jensen, Director of Clinical, Medical and Regulatory, Novo Nordisk, said, "Novo Nordisk is proud to support the TALK Hypos campaign, which aims to improve awareness of hypos as part of Changing Diabetes(R); a global commitment to improving conditions for the millions of people who live with diabetes around the world today, and those who are at risk of developing diabetes tomorrow."

The TALK Hypos campaign comprises patient education materials and an education video that is hosted on the Diabetes UK and Novo Nordisk websites.

Notes to the editor:

To access the TALK Hypos campaign materials via the Novo Nordisk website, please visit: http://www.novonordisk.co.uk [http://novonordisk.co.uk/content/hcp/diabetes/talkhypos.asp ].

About Novo Nordisk

Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit novonordisk.co.uk.

About Diabetes UK

Suggested Articles

A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.

Sanofi and Regeneron recently debuted an unbranded awareness and education campaign around type 2 inflammation and its connections across conditions.

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.